MASCC 2016 | Treating cachecia with anamorelin: 24-week follow-up data from ROMANA studies

Name: Treating cachecia with anamorelin: 24-week follow-up data from ROMANA studies
Uploaded: 2016-06-23T00:00:00.000Z
Duration: 3 min 15 s

David Currow • 23 Jun 2016

MASCC 2016

David Currow, BMed, PhD, MPH, FRACP, FAChPM, FAHMS, GAICD of Flinders University, Adelaide, Australia, discusses anamorelin in ROMANA 1 and ROMANA 2 studies. Anamorelin acts as a selective ghrelin receptor agonist and has a potential to increase lean body mass, appetite, and fat mass in people with cancer cachexia. Dr Currow highlights the 24-week follow-up data from ROMANA studies showing increase in lean body mass and fat mass, and decrease in anorexia, which was maintained in the anamorelin-treated study arm. Cachexia is one of the prognostic factors in cancer and Dr Currow sees this as a tremendous opportunity to open a new therapeutic corridor, which allows us to treat cachexia alongside the disease. Recorded at the Multinational Association of Supportive Care in Cancer (MASCC) 2016 Annual Congress in Adelaide, Australia.